首页 > 最新文献

Jacc: Cardiooncology最新文献

英文 中文
Life’s Essential 8 and Incident Cardiovascular Disease in U.S. Women With Breast Cancer 生活必需品 8 和美国乳腺癌妇女的心血管疾病发病率
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.008
Elena Wadden MD , Alexi Vasbinder PhD, RN , Vidhushei Yogeswaran MD , Aladdin H. Shadyab PhD , Nazmus Saquib MBBS, MPH, PhD , Yangbo Sun PhD , Lisa Warsinger Martin MD , Ramesh Mazhari MD , JoAnn E. Manson MD, DrPH , Marcia Stefanick PhD , Ana Barac MD, PhD , Michael S. Simon MD , Kerryn Reding PhD, MPH, RN , Richard K. Cheng MD, MS

Background

Relationships between lifestyle risk factors and cardiovascular disease (CVD) risk in women with breast cancer (BC) are underexplored.

Objectives

To evaluate the incidence of CVD in relation to the Life’s Essential 8 (LE8) score among women with BC.

Methods

Data from the Women’s Health Initiative were utilized. The primary exposure was the LE8 score assessed prior to BC diagnosis. The LE8 score was stratified into low (0-59), moderate (60-79), and high (80-100) cardiovascular health (CVH). The primary endpoint was a composite of incident CVD events, which included coronary heart disease, defined as myocardial infarction along with coronary revascularization, CVD death, and stroke. We calculated the cumulative incidence of CVD and estimated hazard ratios.

Results

Among 7,165 participants, the median age was 70.1 years at BC diagnosis. The mean LE8 score was 62.0 ± 12.2. Over a median follow-up period of 6 years, 490 composite CVD events occurred. The risk of CVD events was highest for low CVH compared with moderate and high CVH. Compared with low CVH, the hazard ratio for incident CVD was 0.57 (95% CI: 0.46-0.69) for moderate CVH and 0.34 (95% CI: 0.20-0.59) for high CVH. LE8, in conjunction with age, provided a C-statistic of 0.74 for the composite risk of CVD.

Conclusions

Higher LE8 scores were associated with a lower risk of incident CVD among women with BC in the United States.
背景对乳腺癌(BC)女性患者的生活方式风险因素与心血管疾病(CVD)风险之间的关系探索不足。主要暴露是在 BC 诊断前评估的 LE8 分数。LE8 分值被分为低(0-59 分)、中(60-79 分)和高(80-100 分)心血管健康(CVH)等级。主要终点是心血管疾病事件的综合指数,其中包括冠心病(定义为心肌梗死和冠状动脉血运重建)、心血管疾病死亡和中风。我们计算了心血管疾病的累积发病率,并估算了危险比。结果在 7,165 名参与者中,确诊 BC 时的中位年龄为 70.1 岁。LE8 评分的平均值为 62.0 ± 12.2。中位随访期为 6 年,共发生 490 起心血管疾病综合事件。与中度和高度CVH相比,低CVH发生心血管事件的风险最高。与低 CVH 相比,中度 CVH 发生心血管事件的危险比为 0.57(95% CI:0.46-0.69),高度 CVH 为 0.34(95% CI:0.20-0.59)。结论美国 BC 女性患者中,LE8 评分越高,发生心血管疾病的风险越低。
{"title":"Life’s Essential 8 and Incident Cardiovascular Disease in U.S. Women With Breast Cancer","authors":"Elena Wadden MD ,&nbsp;Alexi Vasbinder PhD, RN ,&nbsp;Vidhushei Yogeswaran MD ,&nbsp;Aladdin H. Shadyab PhD ,&nbsp;Nazmus Saquib MBBS, MPH, PhD ,&nbsp;Yangbo Sun PhD ,&nbsp;Lisa Warsinger Martin MD ,&nbsp;Ramesh Mazhari MD ,&nbsp;JoAnn E. Manson MD, DrPH ,&nbsp;Marcia Stefanick PhD ,&nbsp;Ana Barac MD, PhD ,&nbsp;Michael S. Simon MD ,&nbsp;Kerryn Reding PhD, MPH, RN ,&nbsp;Richard K. Cheng MD, MS","doi":"10.1016/j.jaccao.2024.07.008","DOIUrl":"10.1016/j.jaccao.2024.07.008","url":null,"abstract":"<div><h3>Background</h3><div>Relationships between lifestyle risk factors and cardiovascular disease (CVD) risk in women with breast cancer (BC) are underexplored.</div></div><div><h3>Objectives</h3><div>To evaluate the incidence of CVD in relation to the Life’s Essential 8 (LE8) score among women with BC.</div></div><div><h3>Methods</h3><div>Data from the Women’s Health Initiative were utilized. The primary exposure was the LE8 score assessed prior to BC diagnosis. The LE8 score was stratified into low (0-59), moderate (60-79), and high (80-100) cardiovascular health (CVH). The primary endpoint was a composite of incident CVD events, which included coronary heart disease, defined as myocardial infarction along with coronary revascularization, CVD death, and stroke. We calculated the cumulative incidence of CVD and estimated hazard ratios.</div></div><div><h3>Results</h3><div>Among 7,165 participants, the median age was 70.1 years at BC diagnosis. The mean LE8 score was 62.0 ± 12.2. Over a median follow-up period of 6 years, 490 composite CVD events occurred. The risk of CVD events was highest for low CVH compared with moderate and high CVH. Compared with low CVH, the hazard ratio for incident CVD was 0.57 (95% CI: 0.46-0.69) for moderate CVH and 0.34 (95% CI: 0.20-0.59) for high CVH. LE8, in conjunction with age, provided a C-statistic of 0.74 for the composite risk of CVD.</div></div><div><h3>Conclusions</h3><div>Higher LE8 scores were associated with a lower risk of incident CVD among women with BC in the United States.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 746-757"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437649","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Measuring “Cardiovascular Health” in Everyone Including Cancer Patients 衡量包括癌症患者在内的所有人的 "心血管健康 "状况
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.08.003
Tochi M. Okwuosa DO , Donald Lloyd-Jones MD
{"title":"Measuring “Cardiovascular Health” in Everyone Including Cancer Patients","authors":"Tochi M. Okwuosa DO ,&nbsp;Donald Lloyd-Jones MD","doi":"10.1016/j.jaccao.2024.08.003","DOIUrl":"10.1016/j.jaccao.2024.08.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 758-760"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preventing Cancer Therapy–Related Cardiotoxicity 预防与癌症治疗相关的心脏毒性
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.09.001
Antonio Cannata MD , Theresa McDonagh MB ChB, MD
{"title":"Preventing Cancer Therapy–Related Cardiotoxicity","authors":"Antonio Cannata MD ,&nbsp;Theresa McDonagh MB ChB, MD","doi":"10.1016/j.jaccao.2024.09.001","DOIUrl":"10.1016/j.jaccao.2024.09.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 697-698"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437692","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Steroids in Immune Checkpoint Inhibitor Myocarditis 类固醇在免疫检查点抑制剂心肌炎中的应用
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.002
Nicolas L. Palaskas MD, MPH , Bilal A. Siddiqui MD , Anita Deswal MD, MPH
{"title":"Steroids in Immune Checkpoint Inhibitor Myocarditis","authors":"Nicolas L. Palaskas MD, MPH ,&nbsp;Bilal A. Siddiqui MD ,&nbsp;Anita Deswal MD, MPH","doi":"10.1016/j.jaccao.2024.07.002","DOIUrl":"10.1016/j.jaccao.2024.07.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 800-803"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors 利用多基因风险评分预测癌症幸存者的心力衰竭
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.04.010
Cheng Hwee Soh PhD , RuiDong Xiang PhD , Fumihiko Takeuchi PhD , Thomas H. Marwick MBBS, PhD, MPH

Background

The risk for heart failure (HF) is increased among cancer survivors, but predicting individual HF risk is difficult. Polygenic risk scores (PRS) for HF prediction summarize the combined effects of multiple genetic variants specific to the individual.

Objectives

The aim of this study was to compare clinical HF prediction models with PRS in both cancer and noncancer populations.

Methods

Cancer and HF diagnoses were identified using International Classification of Diseases-10th Revision codes. HF risk was calculated using the ARIC (Atherosclerosis Risk in Communities) HF score (ARIC-HF). The PRS for HF (PRS-HF) was calculated according to the Global Biobank Meta-analysis Initiative. The predictive performance of the ARIC-HF and PRS-HF was compared using the area under the curve (AUC) in both cancer and noncancer populations.

Results

After excluding 2,644 participants with HF prior to consent, 440,813 participants without cancer (mean age 57 years, 53% women) and 43,720 cancer survivors (mean age 60 years, 65% women) were identified at baseline. Both the ARIC-HF and PRS-HF were significant predictors of incident HF after adjustment for chronic kidney disease, overall health rating, and total cholesterol. The PRS-HF performed poorly in predicting HF among cancer (AUC: 0.552; 95% CI: 0.539-0.564) and noncancer (AUC: 0.561; 95% CI: 0.556-0.566) populations. However, the ARIC-HF predicted incident HF in the noncancer population (AUC: 0.804; 95% CI: 0.800-0.808) and provided acceptable performance among cancer survivors (AUC: 0.748; 95% CI: 0.737-0.758).

Conclusions

The prediction of HF on the basis of conventional risk factors using the ARIC-HF score is superior compared to the PRS, in cancer survivors, and especially among the noncancer population.
背景癌症幸存者发生心力衰竭(HF)的风险会增加,但预测个体发生 HF 的风险却很困难。用于 HF 预测的多基因风险评分(PRS)总结了个体特有的多种基因变异的综合效应。方法使用国际疾病分类-第 10 次修订代码确定癌症和 HF 诊断。使用社区动脉粥样硬化风险(ARIC)高频评分(ARIC-HF)计算高频风险。根据全球生物库荟萃分析倡议(Global Biobank Meta-analysis Initiative)计算出 HF 的 PRS(PRS-HF)。结果在排除 2644 名同意前患有 HF 的参与者后,基线确定了 440813 名未患癌症的参与者(平均年龄 57 岁,53% 为女性)和 43720 名癌症幸存者(平均年龄 60 岁,65% 为女性)。在对慢性肾病、总体健康评分和总胆固醇进行调整后,ARIC-HF 和 PRS-HF 均可显著预测心房颤动的发生。PRS-HF 在预测癌症人群(AUC:0.552;95% CI:0.539-0.564)和非癌症人群(AUC:0.561;95% CI:0.556-0.566)的房颤方面表现不佳。然而,ARIC-HF 可预测非癌症人群中的 HF 事件(AUC:0.804;95% CI:0.800-0.808),在癌症幸存者中的表现也可接受(AUC:0.748;95% CI:0.737-0.758)。
{"title":"Use of Polygenic Risk Score for Prediction of Heart Failure in Cancer Survivors","authors":"Cheng Hwee Soh PhD ,&nbsp;RuiDong Xiang PhD ,&nbsp;Fumihiko Takeuchi PhD ,&nbsp;Thomas H. Marwick MBBS, PhD, MPH","doi":"10.1016/j.jaccao.2024.04.010","DOIUrl":"10.1016/j.jaccao.2024.04.010","url":null,"abstract":"<div><h3>Background</h3><div>The risk for heart failure (HF) is increased among cancer survivors, but predicting individual HF risk is difficult. Polygenic risk scores (PRS) for HF prediction summarize the combined effects of multiple genetic variants specific to the individual.</div></div><div><h3>Objectives</h3><div>The aim of this study was to compare clinical HF prediction models with PRS in both cancer and noncancer populations.</div></div><div><h3>Methods</h3><div>Cancer and HF diagnoses were identified using International Classification of Diseases-10th Revision codes. HF risk was calculated using the ARIC (Atherosclerosis Risk in Communities) HF score (ARIC-HF). The PRS for HF (PRS-HF) was calculated according to the Global Biobank Meta-analysis Initiative. The predictive performance of the ARIC-HF and PRS-HF was compared using the area under the curve (AUC) in both cancer and noncancer populations.</div></div><div><h3>Results</h3><div>After excluding 2,644 participants with HF prior to consent, 440,813 participants without cancer (mean age 57 years, 53% women) and 43,720 cancer survivors (mean age 60 years, 65% women) were identified at baseline. Both the ARIC-HF and PRS-HF were significant predictors of incident HF after adjustment for chronic kidney disease, overall health rating, and total cholesterol. The PRS-HF performed poorly in predicting HF among cancer (AUC: 0.552; 95% CI: 0.539-0.564) and noncancer (AUC: 0.561; 95% CI: 0.556-0.566) populations. However, the ARIC-HF predicted incident HF in the noncancer population (AUC: 0.804; 95% CI: 0.800-0.808) and provided acceptable performance among cancer survivors (AUC: 0.748; 95% CI: 0.737-0.758).</div></div><div><h3>Conclusions</h3><div>The prediction of HF on the basis of conventional risk factors using the ARIC-HF score is superior compared to the PRS, in cancer survivors, and especially among the noncancer population.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 714-727"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Body Composition During Androgen Deprivation Therapy in Prostate Cancer 前列腺癌雄激素剥夺疗法期间的身体组成
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.08.004
Jie Lee MD, PhD , Jhen-Bin Lin MD
{"title":"Body Composition During Androgen Deprivation Therapy in Prostate Cancer","authors":"Jie Lee MD, PhD ,&nbsp;Jhen-Bin Lin MD","doi":"10.1016/j.jaccao.2024.08.004","DOIUrl":"10.1016/j.jaccao.2024.08.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 772-774"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis 心脏淀粉样变性患者的血液稀释,而非淋巴毛细血管稀释
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.009
Alberto Aimo MD, PhD , Lucrezia Bonino MD , Vincenzo Castiglione MD , Veronica Musetti BSc , Martina Rossetti MD , Alessandra Celi MD , Michele Coceani MD , Michele Emdin MD, PhD , Angela Pucci MD, PhD , Giuseppe Vergaro MD, PhD
{"title":"Rarefaction of Blood, But Not Lymphatic Capillaries, in Patients With Cardiac Amyloidosis","authors":"Alberto Aimo MD, PhD ,&nbsp;Lucrezia Bonino MD ,&nbsp;Vincenzo Castiglione MD ,&nbsp;Veronica Musetti BSc ,&nbsp;Martina Rossetti MD ,&nbsp;Alessandra Celi MD ,&nbsp;Michele Coceani MD ,&nbsp;Michele Emdin MD, PhD ,&nbsp;Angela Pucci MD, PhD ,&nbsp;Giuseppe Vergaro MD, PhD","doi":"10.1016/j.jaccao.2024.07.009","DOIUrl":"10.1016/j.jaccao.2024.07.009","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 797-799"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Autonomic Dysfunction Among Adult Survivors of Childhood Cancer 儿童癌症成年幸存者的自主神经功能障碍
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.09.004
Cezar A. Iliescu MD, Efstratios Koutroumpakis MD, Kaveh Karimzad MD
{"title":"Autonomic Dysfunction Among Adult Survivors of Childhood Cancer","authors":"Cezar A. Iliescu MD,&nbsp;Efstratios Koutroumpakis MD,&nbsp;Kaveh Karimzad MD","doi":"10.1016/j.jaccao.2024.09.004","DOIUrl":"10.1016/j.jaccao.2024.09.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 788-790"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142438301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Anthracycline Cardiotoxicity in Adult Cancer Patients 成人癌症患者的蒽环类药物心脏毒性
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.016
Massimiliano Camilli MD , Carlo Maria Cipolla MD , Susan Dent MD, BSc , Giorgio Minotti MD, PhD , Daniela Maria Cardinale MD, PhD
Since their introduction in the 1960s, anthracyclines have been a significant breakthrough in oncology, introducing dramatic changes in the treatment of solid and hematologic malignancies. Although new-generation targeted drugs and cellular therapies are revolutionizing contemporary oncology, anthracyclines remain the cornerstone of treatment for lymphomas, acute leukemias, and soft tissue sarcomas. However, their clinical application is limited by a dose-dependent cardiotoxicity that can reduce cardiac performance and eventually lead to overt heart failure. The field of cardio-oncology has emerged to safeguard the cardiovascular health of cancer patients receiving these therapies. It focuses on controlling risk factors, implementing preventive strategies, ensuring appropriate surveillance, and managing complications. This state-of-the-art review summarizes the current indications for anthracyclines in modern oncology, explores recent evidence on pathophysiology and epidemiology, and discusses advances in cardioprotection measures in the anthracycline-treated patient. Additionally, it highlights key clinical challenges and research gaps in this area.
自 20 世纪 60 年代问世以来,蒽环类药物在肿瘤学领域取得了重大突破,为实体瘤和血液系统恶性肿瘤的治疗带来了巨大变化。虽然新一代靶向药物和细胞疗法正在彻底改变当代肿瘤学,但蒽环类药物仍然是治疗淋巴瘤、急性白血病和软组织肉瘤的基石。然而,蒽环类药物的临床应用受到剂量依赖性心脏毒性的限制,这种毒性会降低心脏功能,最终导致明显的心力衰竭。为了保护接受这些疗法的癌症患者的心血管健康,肿瘤心脏病学领域应运而生。其重点是控制风险因素、实施预防策略、确保适当的监测以及控制并发症。这篇最新综述总结了蒽环类药物在现代肿瘤学中的适应症,探讨了病理生理学和流行病学方面的最新证据,并讨论了蒽环类药物治疗患者心血管保护措施的进展。此外,它还强调了这一领域的主要临床挑战和研究空白。
{"title":"Anthracycline Cardiotoxicity in Adult Cancer Patients","authors":"Massimiliano Camilli MD ,&nbsp;Carlo Maria Cipolla MD ,&nbsp;Susan Dent MD, BSc ,&nbsp;Giorgio Minotti MD, PhD ,&nbsp;Daniela Maria Cardinale MD, PhD","doi":"10.1016/j.jaccao.2024.07.016","DOIUrl":"10.1016/j.jaccao.2024.07.016","url":null,"abstract":"<div><div>Since their introduction in the 1960s, anthracyclines have been a significant breakthrough in oncology, introducing dramatic changes in the treatment of solid and hematologic malignancies. Although new-generation targeted drugs and cellular therapies are revolutionizing contemporary oncology, anthracyclines remain the cornerstone of treatment for lymphomas, acute leukemias, and soft tissue sarcomas. However, their clinical application is limited by a dose-dependent cardiotoxicity that can reduce cardiac performance and eventually lead to overt heart failure. The field of cardio-oncology has emerged to safeguard the cardiovascular health of cancer patients receiving these therapies. It focuses on controlling risk factors, implementing preventive strategies, ensuring appropriate surveillance, and managing complications. This state-of-the-art review summarizes the current indications for anthracyclines in modern oncology, explores recent evidence on pathophysiology and epidemiology, and discusses advances in cardioprotection measures in the anthracycline-treated patient. Additionally, it highlights key clinical challenges and research gaps in this area.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 655-677"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis 心肌肌钙蛋白 I 和 T 在 ICI 心肌炎筛查、诊断和预后中的应用
IF 12 1区 医学 Q1 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-10-01 DOI: 10.1016/j.jaccao.2024.07.001
Ana Barac MD, PhD , Raymond C. Wadlow MD , John F. Deeken MD , Christopher deFilippi MD
{"title":"Cardiac Troponin I and T in ICI Myocarditis Screening, Diagnosis, and Prognosis","authors":"Ana Barac MD, PhD ,&nbsp;Raymond C. Wadlow MD ,&nbsp;John F. Deeken MD ,&nbsp;Christopher deFilippi MD","doi":"10.1016/j.jaccao.2024.07.001","DOIUrl":"10.1016/j.jaccao.2024.07.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"6 5","pages":"Pages 804-807"},"PeriodicalIF":12.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142437695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Jacc: Cardiooncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1